Pfizer, Inc. (NYSE:PFE) – Equities researchers at Leerink Swann lifted their Q3 2017 earnings estimates for Pfizer in a research note issued to investors on Monday. Leerink Swann analyst S. Fernandez now expects that the biopharmaceutical company will post earnings of $0.64 per share for the quarter, up from their prior estimate of $0.60. Leerink Swann also issued estimates for Pfizer’s FY2020 earnings at $2.75 EPS and FY2021 earnings at $2.88 EPS.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period last year, the firm posted $0.64 EPS. The business’s revenue was down 1.9% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: “Q3 2017 EPS Estimates for Pfizer, Inc. Raised by Leerink Swann (PFE)” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/25/q3-2017-eps-estimates-for-pfizer-inc-raised-by-leerink-swann-pfe.html.

A number of other research analysts also recently issued reports on PFE. Jefferies Group LLC set a $38.00 price target on Pfizer and gave the company a “neutral” rating in a report on Monday, October 16th. Berenberg Bank reaffirmed a “hold” rating and set a $36.00 price target (down from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Cowen and Company set a $43.00 price target on Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Finally, UBS AG reaffirmed a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. Pfizer presently has an average rating of “Hold” and a consensus target price of $38.26.

Shares of Pfizer (NYSE PFE) opened at 36.27 on Wednesday. The stock has a market capitalization of $215.71 billion, a price-to-earnings ratio of 26.53 and a beta of 1.00. The stock’s 50 day moving average price is $35.65 and its 200 day moving average price is $33.86. Pfizer has a 12 month low of $29.83 and a 12 month high of $36.78.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.53%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio is currently 94.12%.

In related news, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares in the company, valued at $5,074,379. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sally Susman sold 38,230 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock valued at $15,813,961 in the last quarter. 0.06% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in PFE. Bank of The West grew its position in shares of Pfizer by 10.9% during the first quarter. Bank of The West now owns 182,512 shares of the biopharmaceutical company’s stock worth $6,244,000 after purchasing an additional 18,004 shares in the last quarter. Greylin Investment Mangement Inc. grew its position in shares of Pfizer by 17.6% during the first quarter. Greylin Investment Mangement Inc. now owns 53,826 shares of the biopharmaceutical company’s stock worth $1,841,000 after purchasing an additional 8,050 shares in the last quarter. Coastline Trust Co grew its position in shares of Pfizer by 0.7% during the first quarter. Coastline Trust Co now owns 112,970 shares of the biopharmaceutical company’s stock worth $3,864,000 after purchasing an additional 770 shares in the last quarter. Benin Management CORP grew its position in shares of Pfizer by 7.8% during the first quarter. Benin Management CORP now owns 15,614 shares of the biopharmaceutical company’s stock worth $534,000 after purchasing an additional 1,134 shares in the last quarter. Finally, WealthTrust Arizona LLC grew its position in shares of Pfizer by 7.1% during the first quarter. WealthTrust Arizona LLC now owns 7,594 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 505 shares in the last quarter. Hedge funds and other institutional investors own 69.00% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.